解毒逐瘀方保留灌肠治疗早中期慢性重型肝炎患者的临床观察

Clinical Observation on Chronic Severe Hepatitis at Early-Middle Stage Treated with Retention Enema of JieDu ZhuYuFang

目的:观察解毒逐瘀方治疗早中期慢性重型肝炎(chronic severe hepatitis,CSH)的临床疗效。方法:将79例早中期CSH患者根据是否接受中药灌肠分为灌肠组31例,对照组48例。对照组以常规西药治疗;灌肠组常规西药口服联合解毒逐瘀方100 mL灌肠治疗,1次/d。观察患者肝功能、凝血功能变化及并发症、生存率情况。结果:灌肠组可降低早中期CSH患者ALT、AST、TBiL、DBiL水平,提高总胆固醇含量(P<0.05);与对照组相比,灌肠组对ALT、AST、DBiL及TC的改善程度更为显著(P<0.05)。灌肠组可显著缩短早中期CSH患者凝血酶原时间,提高凝血酶原活动度(P<0.05);与对照组相比,灌肠组改善程度更为显著(P<0.05)。灌肠组可有效减少早中期CSH患者并发症,提高生存率,与对照组相比,差异有统计学意义(P<0.05)。结论:解毒逐瘀方可有效改善早中期CSH患者肝功能及凝血功能,减少并发症发生,提高生存率,临床疗效较好。

Objective： To observe clinical effects of JieDu ZhuYuFang in treating chronic severe hepatitis at early and middle stage. Method： A total of 79 patients were divided into 31 cases in enema group and 48 cases in control group according to receiving enema or not. Control group received routine western medicine; enema group received routine western medicine and retention enema with 100 ml ofJieDu ZhuYuFang, once per day. Liver function, blood coagulation function, complication and survival rates of patients were observed. Result： ALT, AST, TBiL and DBiL of patients in enema group decreased, content of total cholesterol increased （P〈0.05）; compared with control group, enema group improved more greatly in ALT, AST, DBiL and TC （P〈0.05）. Time of prothrombin shortened notably in enema group and the activity improved （P〈0.05）; enema group improved significantly compared with compared with control group （P〈0.05）. Complications of patients in enema group decreased, survival rate improved, comparison with control group showed statistical meaning （P〈0.05）. Conclusion： JieDu ZhuYuFang can effectively improve liver func- tion and coagulation of patients with chronic severe hepatitis at early and middle stage with better clinical effects, de- crease complication and raise survival rate.